RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Daviddal, I'm not sure I follow you on the the CX-717 ADHD Phase 2b strategy - are you saying that Cortex would start the Phase 2b and then do the BP deal mid-trial? Wouldn't it be more likely to either 1) outlicense it now and let the BP run the Phase 2b, or 2) have Cortex run the entire Phase 2b in-house until completion and then do the BP deal?

Also, Concerning the Org-24448 Schizo combo Phase 2b, I assume you're referring to the "ATP Group" trial, since TURNS/NIMH isn't happening? Or is Organon doing another combo Schizo trial in addition to the one by the CRO "ATP Group"? Thanks.

Personally I'd like to see Cortex pursue a strategy that dispenses with the need for the non-Ampakine in-licensing altogether.